Zelicapavir for RSV in infants and toddlers
Part of Infections clinical trials.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has tested positive for RSV using a standard test, and does not also have COVID-19 or flu.
- Your child’s RSV symptoms started within the last 3 days (72 hours).
- Your child is at least 28 days old and not older than 36 months (3 years).
- Your child does not have a weak immune system (except for IgA deficiency).
- Your child has not had major surgery in the past 6 weeks, and none is planned during the study.
- Your child is not taking medicines that weaken the immune system (other than steroids for 5 days or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This study tests a new antibody shot (called enflonsia) to help protect babies under 8 months old from RSV, a common virus that can cause breathing problems. If your baby qualifies, they will receive the shot and be followed for about 6 months to see how well it works.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.